Neoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC)

J. K. Litton; S. L. Moulder; K. R. Hess; S. Damodaran; G. M. Rauch; R. Candelaria; B. E. Adrada; F. Symmans; R. K. Murthy; T. Helgason; A. Clayborn; S. Prabhakaran; V. Valero; A. M. Thompson; E. A. Mittendorf

doi:10.1093/annonc/mdy270.219

Neoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC)

J. K. Litton, S. L. Moulder, K. R. Hess, S. Damodaran, G. M. Rauch, R. Candelaria, B. E. Adrada, F. Symmans, R. K. Murthy, T. Helgason, A. Clayborn, S. Prabhakaran, V. Valero, A. M. Thompson, E. A. Mittendorf

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	viii72
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy270.219
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy270.219

Cite this

Litton, J. K., Moulder, S. L., Hess, K. R., Damodaran, S., Rauch, G. M., Candelaria, R., Adrada, B. E., Symmans, F., Murthy, R. K., Helgason, T., Clayborn, A., Prabhakaran, S., Valero, V., Thompson, A. M., & Mittendorf, E. A. (2018). Neoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC). Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii72. https://doi.org/10.1093/annonc/mdy270.219

Neoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC). / Litton, J. K.; Moulder, S. L.; Hess, K. R. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii72.

Research output: Contribution to journal › Article › peer-review

Litton, JK, Moulder, SL, Hess, KR, Damodaran, S , Rauch, GM , Candelaria, R , Adrada, BE, Symmans, F, Murthy, RK, Helgason, T, Clayborn, A, Prabhakaran, S, Valero, V, Thompson, AM & Mittendorf, EA 2018, 'Neoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC)', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii72. https://doi.org/10.1093/annonc/mdy270.219

Litton JK, Moulder SL, Hess KR, Damodaran S , Rauch GM , Candelaria R et al. Neoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii72. doi: 10.1093/annonc/mdy270.219

@article{2c2037e6b8264bc0a97763f823f06c03,

title = "Neoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC)",

author = "Litton, {J. K.} and Moulder, {S. L.} and Hess, {K. R.} and S. Damodaran and Rauch, {G. M.} and R. Candelaria and Adrada, {B. E.} and F. Symmans and Murthy, {R. K.} and T. Helgason and A. Clayborn and S. Prabhakaran and V. Valero and Thompson, {A. M.} and Mittendorf, {E. A.}",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy270.219",

language = "English (US)",

volume = "29",

pages = "viii72",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Neoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC)

AU - Litton, J. K.

AU - Moulder, S. L.

AU - Hess, K. R.

AU - Damodaran, S.

AU - Rauch, G. M.

AU - Candelaria, R.

AU - Adrada, B. E.

AU - Symmans, F.

AU - Murthy, R. K.

AU - Helgason, T.

AU - Clayborn, A.

AU - Prabhakaran, S.

AU - Valero, V.

AU - Thompson, A. M.

AU - Mittendorf, E. A.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85069978025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069978025&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy270.219

DO - 10.1093/annonc/mdy270.219

M3 - Article

C2 - 32137989

SN - 0923-7534

VL - 29

SP - viii72

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Neoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this